| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/03/2001 | CN1278830A Ultra-fine microcrystalline cellulose compositions and process for their manufacture |
| 01/03/2001 | CN1278785A Vanadium complexes of monohydroxamates and pharmaceutical compositions comprising them |
| 01/03/2001 | CN1278739A Method of delivering genes to antigen presenting cells of the skin |
| 01/03/2001 | CN1278738A Release-sustaining agent for drugs and sustained-release pharmaceutical composition containing same |
| 01/03/2001 | CN1278737A Method for decreasing self-association of polypeptides |
| 01/03/2001 | CN1278735A Vaginal suppository vaccine for urogenital infections |
| 01/03/2001 | CN1278733A Viscous compositions containing carbon dioxide |
| 01/03/2001 | CN1278723A Percutaneously absorbable preparation |
| 01/03/2001 | CN1060178C Derivatives of structurally modified vip and pharmacetical compositions containing them for treating servual impotense of male |
| 01/03/2001 | CN1060164C SIN-IA cyclodextriun inclusion complexes |
| 01/03/2001 | CN1060042C Stabilized prostaglandin E1 |
| 01/03/2001 | CN1060041C Aqueous composition |
| 01/03/2001 | CN1060040C A stable pharmaceutical composition of terfenadine and isuprofen |
| 01/02/2001 | US6169118 Two flavoring oils and lauryl alcohol for use in an orally administered formulation |
| 01/02/2001 | US6169117 Increasing the oxygen concentration of the blood while avoiding the formation of bubbles which tend to occlude capillaries |
| 01/02/2001 | US6169084 2-methyl-thieno-benzodiazepine formulation |
| 01/02/2001 | US6169083 Administering an l-carnosine zinc salt or l-carnosine-zinc complex; treating the side effect of cancer chemotherapy or radiotherapy |
| 01/02/2001 | US6169078 Materials and methods for the intracellular delivery of substances |
| 01/02/2001 | US6168806 Orally administrable nifedipine pellet and process for the preparation thereof |
| 01/02/2001 | US6168801 Controlled release drug delivery |
| 01/02/2001 | US6168799 β-D-glucan topical composition |
| 01/02/2001 | US6168796 Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides |
| 01/02/2001 | US6168783 Antagonists of interleukin-15 |
| 01/02/2001 | US6168777 In vivo delivery of radioactive compositions which are delivered as a fluid to the solid mass tumor; subsequent solidification of this composition in the prostate results in delivery of a controlled amount of radiation to the prostate. |
| 01/02/2001 | CA2228932C Use of plasminogen activators to stimulate local bone growth |
| 01/02/2001 | CA2158001C Calcium fortified beverages |
| 01/02/2001 | CA2148571C Sunscreen compositions |
| 01/02/2001 | CA2075060C Novel vehicle gases and their use in medical preparations |
| 01/02/2001 | CA2027596C Compositions containing hyaluronic acid complexes with zinc or cobalt |
| 01/02/2001 | CA2019218C Magnetic protein conjugates, a process for the preparation thereof and the use thereof |
| 12/30/2000 | CA2313011A1 Encapsulation of active ingredients |
| 12/29/2000 | CA2313175A1 High-concentration flowable anionic surfactant mixtures |
| 12/28/2000 | WO2000078949A1 Icbp90 polypeptide and its fragments and polynucleotides coding for said polypeptides and applications for diagnosing and treating cancer |
| 12/28/2000 | WO2000078941A2 Methods and products for manipulating uncoupling protein expression |
| 12/28/2000 | WO2000078805A1 Peptide having preptin functionality |
| 12/28/2000 | WO2000078796A2 Labeled neurotensin derivatives with improved resistance to enzymatic degradation |
| 12/28/2000 | WO2000078792A1 Method for purification of proteins |
| 12/28/2000 | WO2000078791A2 FUNCTIONAL POLY-α-AMINOACID DERIVATIVES USEFUL FOR THE MODIFICATION OF BIOLOGICALLY ACTIVE MATERIALS AND THEIR APPLICATION |
| 12/28/2000 | WO2000078364A2 Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood |
| 12/28/2000 | WO2000078361A2 Methods of imaging and targeting tumor vasculature |
| 12/28/2000 | WO2000078359A2 Compositions for treating chemotherapy-resistant tumor cells |
| 12/28/2000 | WO2000078358A2 Hyaluronic acid microspheres for sustained gene transfer |
| 12/28/2000 | WO2000078357A2 Hyaluronic acid film and matrix for sustained gene transfer |
| 12/28/2000 | WO2000078356A1 Injectable hyaluronate-sulfated polysaccharide conjugates |
| 12/28/2000 | WO2000078355A2 Biologically active materials |
| 12/28/2000 | WO2000078354A1 Topical composition comprising acetyl salicylic acid |
| 12/28/2000 | WO2000078353A2 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
| 12/28/2000 | WO2000078348A1 Autologous adoptive immunotherapy with primed antigen-specific t cells or b cells |
| 12/28/2000 | WO2000078346A1 Novel anti-allergic agents |
| 12/28/2000 | WO2000078340A1 Sustained release preparations of physiologically active peptides |
| 12/28/2000 | WO2000078335A1 COMPOSITIONS FOR CONTROLLED RELEASE OF THE HORMONE GnRH AND ITS ANALOGS |
| 12/28/2000 | WO2000078332A2 Fish serine proteinases and their pharmaceutical and cosmetic use |
| 12/28/2000 | WO2000078318A1 Medicinal composition for oral administration |
| 12/28/2000 | WO2000078304A1 V.n. vassiliev's pharmaceutical composition for restoring the sympatho-adrenal system and method for estimating the efficiency thereof |
| 12/28/2000 | WO2000078302A1 Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same |
| 12/28/2000 | WO2000078301A1 Anesthetic composition for intravenous injection comprising propofol |
| 12/28/2000 | WO2000078297A2 Stable xylometazoline and oxymetazoline solution |
| 12/28/2000 | WO2000078293A1 New formulation |
| 12/28/2000 | WO2000078289A1 Multilayered tablet for administration of a fixed combination of tramadol and diclofenac |
| 12/28/2000 | WO2000078286A1 Steroid solution aerosol products with enhanced chemical stability |
| 12/28/2000 | WO2000078285A1 Controlled release of therapeutics by in-situ entrapment by matrix cross-linking |
| 12/28/2000 | WO2000078283A1 Stable l-ascorbic acid composition |
| 12/28/2000 | WO2000078275A2 Antibacterial compositions |
| 12/28/2000 | WO2000078272A2 Guerbet alcohols |
| 12/28/2000 | WO2000078259A1 Enhanced wound coverage to enhance wound healing |
| 12/28/2000 | WO2000078247A1 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 12/28/2000 | WO2000078149A1 Anthelmintic compositions |
| 12/28/2000 | WO2000056325A3 Ibuprofen solution |
| 12/28/2000 | WO2000054754A3 Composition comprising isoquercetin and ascorbic acid in a sustained release form |
| 12/28/2000 | WO2000050085A3 Oil-in-water emulsion for the use as medicament or for producing a medicament |
| 12/28/2000 | WO2000045845A3 Liposome composition and method for administration of a radiosensitizer |
| 12/28/2000 | WO2000043034A3 Monodisperse hexameric acylated insulin analog formulations |
| 12/28/2000 | DE19929197A1 Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung Transdermal systems for the delivery of 5-HT3 receptor antagonists and their use for the treatment antiemitischen |
| 12/28/2000 | DE19929104A1 Vector complex, useful for gene therapy of e.g. tumors, comprises nucleic acid, cationic carrier, charged polymer and targeting ligand |
| 12/28/2000 | DE19922662C1 Transdermales therapeutisches System (TTS) Tolterodin enthaltend Transdermal therapeutic system (TTS) containing tolterodine |
| 12/28/2000 | CA2778826A1 Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same |
| 12/28/2000 | CA2378051A1 Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood |
| 12/28/2000 | CA2377524A1 Novel anti-allergic agents |
| 12/28/2000 | CA2377517A1 Amphiphilic drug-oligomer conjugates with hydrolyzable lipophile components and methods for making and using the same |
| 12/28/2000 | CA2377371A1 Enhanced wound coverage to enhance wound healing |
| 12/28/2000 | CA2377357A1 Fish serine proteinases and their pharmaceutical and cosmetic use |
| 12/28/2000 | CA2377267A1 Functional poly-.alpha.-aminoacid derivatives useful for the modification of biologically active materials and their application |
| 12/28/2000 | CA2377188A1 Methods of imaging and targeting tumor vasculature |
| 12/28/2000 | CA2376829A1 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a |
| 12/28/2000 | CA2376155A1 Pharmaceutical composition for oral use |
| 12/28/2000 | CA2375508A1 Methods and products for manipulating uncoupling protein expression |
| 12/28/2000 | CA2375207A1 Peptide having preptin functionality |
| 12/28/2000 | CA2374548A1 Biologically active materials |
| 12/28/2000 | CA2374270A1 Labeled neurotensin derivatives |
| 12/28/2000 | CA2371931A1 Steroid solution aerosol products with enhanced chemical stability |
| 12/28/2000 | CA2371924A1 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 12/27/2000 | EP1063254A1 Copolymers for the transport of nucleic acids in the cell |
| 12/27/2000 | EP1063241A1 Pharmaceutical preparations comprising thioctic acid or dihydrolipoic acid in the form of inclusion compounds with cyclodextrins oder cyclodextrin derivatives and in the form of granulates, chewing-or effervescent tablets |
| 12/27/2000 | EP1062952A1 Bubbling enteric coated preparations |
| 12/27/2000 | EP1062945A1 Directly compressible starch as enhancer of properties of excipients when used as binder and disintegrant for compression tablets |
| 12/27/2000 | EP1062259A1 Biodegradable polymers based on natural and renewable raw materials, especially isosorbite |
| 12/27/2000 | EP1062232A2 Molecules that home to various selected organs or tissues |
| 12/27/2000 | EP1062230A1 Method for increasing the serum half-life of a biologically active molecule |
| 12/27/2000 | EP1062229A1 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| 12/27/2000 | EP1062223A1 Composition containing a precursor capable of being hydrolysed by glucocerebrosidase |